Palatin WKN: A3DTUW ISIN: US6960775020 Kürzel: PTN Forum: Aktien User: allesaufaurora

Für diese Meldung bisl mau der Kurs

https://www.prnewswire.com/news-releases/palatin-issued-patent-on-vyleesi-bremelanotide-injection-for-hypoactive-sexual-desire-disorder-in-patients-with-controlled-hypertension-301757636.html

Michael Higgins and Joe Pantginis are getting paid by PTN to make false propaganda. They receive the questions PTN wants to hear. Find their Emails and write to them! They are complicit in this fraud! They are not going to read this forum; We must organize and force those scammers to rectify. Write them many Emails!

September 22, 2022. "The primary objective is to relicense it (Vyleesi). I want to be clear that Carl's objective and my objective (Stephen T. Wills) is to license the product, ...the primary objective is to license it by year-end." If they said that, is because they have advanced conversations with someone. But after 5 months nothing has been said about it, it makes me think that they are lying to deceive investors. Later on February 15, 2023 Steve Wills said after only 1 question: "All right. I'll jump in since we have that bit of an awkward silence. I think we're having a little trouble with the Q&A" Crap! Bullshit! They were scared that someone ask you about that "license it by year-end". Everyone must write emails to Carl Spana and Steve Wills. Make them aware that many investors are getting upset. Maybe they get scared and begin to do the right things! They are not going to read this forum; We must organize and force those scammers to rectify.

Der Kurssturz auf L&S ist nicht nachvollziehbar

Schön, dass die Kostenseite immer mehr im Griff ist. Hoffen wir weiter auf einen Durchbruch bei den Studien.

Rakeeeete ?!

Palatin Tech press release (NYSE:PTN): Q2 GAAP EPS of -$0.13 beats by $0.33. Revenue of $1.03M (+221.9% Y/Y) misses by $3.39M. Total prescriptions dispensed increased 12% over the prior quarter and increased 134% over the comparable quarter last year. Refill rates, commercial insurance reimbursement, and net revenue per prescription dispensed increased over the prior quarter and comparable quarter last year.

Go go go

Palatin starts mid-stage study of bremelanotide for diabetic kidney disease. We now have three active melanocortin-based clinical programs: our MELODY-1 Phase 3 dry eye disease trial, a Phase 2 ulcerative colitis trial and a Phase 2 diabetic kidney disease trial, all with data readouts throughout calendar year 2023.

Palatin secures $4.7M of non-dilutive funding. Palatin Technologies (NYSE:PTN) has received ~$4.7M of non-dilutive funding through the New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program, which allow to convert certain state operating losses into tangible working capital.

Nachgekauft ✅

EK 15,77 holding on 😉

Step by step…, hoffe dass wir für unsere Geduld noch alle ordentlich belohnt werden.